Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Cardiovascular4053 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03993 | 33798787 | Cell Mol Gastroenterol Hepatol | Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver. | 2021 | Details |
| A03999 | 33794784 | BMC Gastroenterol | A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. | 2021 | Details |
| A04033 | 33782808 | Dig Dis Sci | Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. | 2021 | Details |
| A04046 | 33777158 | Evid Based Complement Alternat Med | Hepatocardiac or Cardiohepatic Interaction: From Traditional Chinese Medicine to Western Medicine. | 2021 | Details |
| A04047 | 33776934 | Front Endocrinol (Lausanne) | The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study. | 2021 | Details |
| A04048 | 33776901 | Front Endocrinol (Lausanne) | Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. | 2021 | Details |
| A04050 | 33776471 | Int J Gen Med | The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms. | 2021 | Details |
| A04051 | 33776366 | World J Gastroenterol | Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. | 2021 | Details |
| A04052 | 33775894 | Clin Gastroenterol Hepatol | Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. | 2021 | Details |
| A04058 | 33773656 | Food Res Int | Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. | 2021 | Details |
| A04061 | 33772908 | Biofactors | The role of biofactors in the prevention and treatment of age-related diseases. | 2021 | Details |
| A04076 | 33768700 | J Dtsch Dermatol Ges | Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? | 2021 | Details |
| A04079 | 33767944 | Curr Hepatol Rep | Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A04088 | 33764550 | Aliment Pharmacol Ther | Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A04089 | 33763391 | Can J Gastroenterol Hepatol | Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. | 2021 | Details |
| A04116 | 33751877 | Clin Mol Hepatol | From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? | 2021 | Details |
| A04129 | 33746450 | J Clin Exp Hepatol | Long-term Management of the Adult Liver Transplantation Recipients. | 2020 | Details |
| A04139 | 33744170 | Dig Liver Dis | Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. | 2021 | Details |
| A04142 | 33743323 | Nutr Res | Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. | 2020 | Details |
| A04146 | 33742318 | Curr Diab Rep | The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. | 2021 | Details |
| A04151 | 33740211 | Hepatol Int | Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. | 2021 | Details |
| A04152 | 33739984 | PLoS One | Association between sarcopenia level and metabolic syndrome. | 2021 | Details |
| A04162 | 33732887 | JGH Open | Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans. | 2021 | Details |
| A04163 | 33732030 | Clin Pharmacol | Clinical Impact of Liraglutide as a Treatment of Obesity. | 2021 | Details |
| A04166 | 33731579 | Eur J Gastroenterol Hepatol | Association between nonalcoholic fatty liver disease and cardiovascular disease revealed after comprehensive control of metabolic risk factors: a nationwide population-based study in Korea. | 2021 | Details |
| A04176 | 33727658 | Commun Biol | Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes. | 2021 | Details |
| A04189 | 33722690 | Mol Metab | Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. | 2021 | Details |
| A04190 | 33722154 | Adipocyte | Dysfunctional adiposity index as a marker of adipose tissue morpho-functional abnormalities and metabolic disorders in apparently healthy subjects. | 2021 | Details |
| A04195 | 33720570 | Ter Arkh | [Clinical and prognostic value of metabolic disorders in non-alcoholic fatty liver disease]. | 2020 | Details |
| A04203 | 33716447 | World J Gastroenterol | G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. | 2021 | Details |
| A04204 | 33716004 | Metabolism | Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. | 2021 | Details |
| A04206 | 33714861 | Complement Ther Clin Pract | Effect of green coffee bean extract supplementation on liver function and inflammatory biomarkers: A meta-analysis of randomized clinical trials. | 2021 | Details |
| A04208 | 33713286 | Intern Emerg Med | Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. | 2021 | Details |
| A04226 | 33708118 | Front Pharmacol | Astragaloside IV Improves High-Fat Diet-Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway. | 2021 | Details |
| A04227 | 33707081 | Best Pract Res Clin Endocrinol Metab | Gut microbiome and bile acids in obesity-related diseases. | 2021 | Details |
| A04228 | 33706959 | Vitam Horm | Ghrelin and adipokines: An overview of their physiological role, antimicrobial activity and impact on cardiovascular conditions. | 2021 | Details |
| A04234 | 33703947 | J Appl Physiol (1985) | High fat high sucrose diet-induced dyslipidemia in guinea pigs. | 2021 | Details |
| A04236 | 33694066 | Hepatol Int | Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? | 2021 | Details |
| A04240 | 33693480 | Cardiovasc Res | Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. | 2022 | Details |
| A04244 | 33692700 | Front Physiol | Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. | 2021 | Details |
| A04268 | 33683797 | Int J Clin Pract | The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. | 2021 | Details |
| A04281 | 33679048 | J Clin Exp Hepatol | The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. | 2020 | Details |
| A04291 | 33675475 | Int Urol Nephrol | Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. | 2021 | Details |
| A04298 | 33672864 | Life (Basel) | FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. | 2021 | Details |
| A04334 | 33660958 | Croat Med J | Non-alcoholic fatty liver disease - a procoagulant condition? | 2021 | Details |
| A04341 | 33658436 | Mol Cells | Increased Hepatic Lipogenesis Elevates Liver Cholesterol Content. | 2021 | Details |
| A04348 | 33653293 | BMC Gastroenterol | Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study. | 2021 | Details |
| A04352 | 33652261 | Biomed Pharmacother | Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. | 2021 | Details |
| A04359 | 33648515 | Cardiovasc Diabetol | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. | 2021 | Details |
| A04360 | 33647942 | Endocrinology | Hepatic Igf1-Deficiency Protects Against Atherosclerosis in Female Mice. | 2021 | Details |
| A04362 | 33647823 | Int Immunopharmacol | The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. | 2021 | Details |
| A04376 | 33642551 | Biol Pharm Bull | Deletion of TRPC3 or TRPC6 Fails to Attenuate the Formation of Inflammation and Fibrosis in Non-alcoholic Steatohepatitis. | 2021 | Details |
| A04402 | 33632113 | Endocr Metab Immune Disord Drug Targets | Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. | 2022 | Details |
| A04414 | 33628193 | Front Pharmacol | Fructose and Non-Alcoholic Steatohepatitis. | 2021 | Details |
| A04423 | 33622213 | Am J Chin Med | Intestinal Flora: A Pivotal Role in Investigation of Traditional Chinese Medicine. | 2021 | Details |
| A04432 | 33618508 | Clin Mol Hepatol | Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. | 2021 | Details |
| A04488 | 33598647 | JHEP Rep | Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. | 2020 | Details |
| A04512 | 33592910 | Medicine (Baltimore) | Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis. | 2021 | Details |
| A04522 | 33588049 | Free Radic Biol Med | Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. | 2021 | Details |
| A04528 | 33586354 | ESC Heart Fail | Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. | 2021 | Details |
| A04532 | 33585266 | Front Cell Infect Microbiol | The Role of Porphyromonas gingivalis Outer Membrane Vesicles in Periodontal Disease and Related Systemic Diseases. | 2021 | Details |
| A04533 | 33585157 | Curr Hepatol Rep | Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. | 2020 | Details |
| A04547 | 33583033 | Eur J Clin Invest | Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. | 2021 | Details |
| A04565 | 33578702 | Antioxidants (Basel) | Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. | 2021 | Details |
| A04580 | 33573891 | J Diabetes Complications | Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes. | 2021 | Details |
| A04581 | 33573745 | J Am Coll Cardiol | Leptin in Leanness and Obesity: JACC State-of-the-Art Review. | 2021 | Details |
| A04594 | 33569991 | Arch Physiol Biochem | The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review. | 2021 | Details |
| A04595 | 33569851 | J Gastroenterol Hepatol | Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2021 | Details |
| A04600 | 33567710 | Int J Environ Res Public Health | Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. | 2021 | Details |
| A04608 | 33564868 | Am J Clin Nutr | Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study. | 2021 | Details |
| A04614 | 33562458 | Pharmaceuticals (Basel) | The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. | 2021 | Details |
| A04618 | 33561256 | J Nutr | Dietary Fruit and Vegetable Supplementation Suppresses Diet-Induced Atherosclerosis in LDL Receptor Knockout Mice. | 2021 | Details |
| A04620 | 33560053 | J Hypertens | Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. | 2021 | Details |
| A04641 | 33554097 | JHEP Rep | Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. | 2020 | Details |
| A04657 | 33549735 | Ann Hepatol | Hepatic steatosis and respiratory diseases: a new panorama. | 2021 | Details |
| A04688 | 33541866 | Gut | Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? | 2021 | Details |
| A04693 | 33538526 | Gastroenterol Nurs | Gut Microbiome and Nonalcoholic Fatty Liver Disease (NAFLD): Implications for Nursing Care of Individuals Living With Chronic Metabolic Diseases. | 2021 | Details |
| A04694 | 33537464 | Biochem Biophys Rep | A high methionine and low folate diet alters glucose homeostasis and gut microbiome. | 2021 | Details |
| A04703 | 33535211 | Dig Dis | NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea. | 2021 | Details |
| A04706 | 33534958 | ESC Heart Fail | Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. | 2021 | Details |
| A04708 | 33534815 | PLoS One | Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. | 2021 | Details |
| A04716 | 33530440 | J Clin Med | NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. | 2021 | Details |
| A04724 | 33527637 | Liver Int | National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. | 2021 | Details |
| A04728 | 33525625 | Molecules | The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. | 2021 | Details |
| A04740 | 33518166 | Gastroenterol Clin North Am | The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04756 | 33514365 | Cardiovasc Diabetol | Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study. | 2021 | Details |
| A04781 | 33506689 | J Am Heart Assoc | Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. | 2021 | Details |
| A04784 | 33505944 | Can J Gastroenterol Hepatol | Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. | 2021 | Details |
| A04797 | 33503878 | Nutrients | Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. | 2021 | Details |
| A04806 | 33498684 | Plants (Basel) | Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. | 2021 | Details |
| A04809 | 33498410 | J Clin Med | Hepatokines as a Molecular Transducer of Exercise. | 2021 | Details |
| A04815 | 33496858 | J Gastroenterol | Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database. | 2021 | Details |
| A04868 | 33475559 | J Pak Med Assoc | Non-alcoholic fatty liver disease: A real threat in Pakistan. | 2020 | Details |
| A04872 | 33473004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | Progress in the study on innate immunity and non-alcohol fatty liver disease. | 2020 | Details |
| A04896 | 33461969 | BMJ | Management of non-alcoholic fatty liver disease. | 2021 | Details |
| A04906 | 33456595 | J Med Life | Transgenerational Effects of Traumatic Historical Events on the Incidence of Metabolic Syndrome/ Nonalcoholic Fatty Liver Disease in the Romanian Population. | 2021 | Details |
| A04924 | 33447122 | Clin Med Insights Endocrinol Diabetes | Oral GLP1 Analog: Where Does the Tide Go? | 2020 | Details |
| A04929 | 33445827 | Epidemiol Health | Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. | 2020 | Details |
| A04930 | 33445755 | Antioxidants (Basel) | Targeting Autophagy to Counteract Obesity-Associated Oxidative Stress. | 2021 | Details |
| A04937 | 33444606 | Metabolism | Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. | 2021 | Details |